HDAC9 and Alzheimer disease: Recent work shows that pan-HDAC inhibitor VPA, as well as WT161, a novel HDAC6 selective inhibitor primarily used in tumor treatment, effectively reduced Aβ deposition in both AD cell and mouse models [134].